Clinical Trials in Auburn Hills, Michigan
18 recruiting
Showing 1–18 of 18 trials
Recruiting
Phase 2
Pharmacokinetics, Safety, and Efficacy of Povorcitinib in Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS)
Incyte Corporation40 enrolled27 locationsNCT07213973
Recruiting
Phase 3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Hidradenitis Suppurativa (HS)
Incyte Corporation600 enrolled318 locationsNCT06855498
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
Prurigo Nodularis
Incyte Corporation330 enrolled120 locationsNCT06516952
Recruiting
Phase 3
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
Plaque Psoriasis
Bristol-Myers Squibb3,040 enrolled357 locationsNCT07116967
Recruiting
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
Atopic Dermatitis
Sanofi1,000 enrolled43 locationsNCT07290803
Recruiting
Phase 2
A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis
Atopic Dermatitis (AD)
Bluefin Biomedicine, Inc.225 enrolled55 locationsNCT07105488
Recruiting
Phase 2Phase 3
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus Erythematosus
Biogen450 enrolled314 locationsNCT05531565
Recruiting
Phase 2
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
Atopic Dermatitis (AD)
Enveda Therapeutics60 enrolled17 locationsNCT07298395
Recruiting
Phase 2
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
Subacute Cutaneous Lupus ErythematosusChronic Cutaneous Lupus Erythematosus
Immunovant Sciences GmbH56 enrolled86 locationsNCT06980805
Recruiting
Phase 3
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
Atopic Dermatitis
Organon and Co180 enrolled48 locationsNCT07265479
Recruiting
Phase 3
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
Hidradenitis Suppurativa
Incyte Corporation550 enrolled107 locationsNCT06958211
Recruiting
Phase 2Phase 3
A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS)
Bluefin Biomedicine, Inc.210 enrolled33 locationsNCT07287644
Recruiting
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
Atopic Dermatitis
Galderma R&D1,000 enrolled108 locationsNCT06988605
Recruiting
Real-world Experience on Using Nemolizumab in the Treatment of Moderate-to- Severe Prurigo Nodularis in Adults
Prurigo Nodularis
Galderma R&D600 enrolled51 locationsNCT06988618
Recruiting
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
Alopecia Areata
Pfizer850 enrolled58 locationsNCT06531109
Recruiting
Phase 3
Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata
Alopecia Areata
Sun Pharmaceutical Industries, Inc.355 enrolled64 locationsNCT07133308
Recruiting
Mymobility Knee ROM
Knee Range of Motion
Zimmer Biomet41 enrolled1 locationNCT06863428
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
Atopic Dermatitis
Incyte Corporation240 enrolled96 locationsNCT06832618